Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Next Previous
Search
Trial Profile

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Aggression
  • Focus Adverse reactions; First in man
  • Acronyms REIMAGINE
  • Sponsors Oryzon

    • Most Recent Events

    • 14 Feb 2025 According to an Oryzon media release, the final results of the Phase IIa REIMAGINE study, which evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD), were published online in Psychiatry and Clinical Neurosciences.
    • 15 Jun 2021 According to an Oryzon media release, PORTICO builds on clinical data from the Phase IIa REIMAGINE trial.
    • 06 Jul 2020 Results presented in an Oryzon Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top